HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis

Advanced targeted therapies including tumour necrosis factor inhibitors (TNFis) have transformed the clinical management of rheumatoid arthritis (RA). However, monoclonal antibody (MAb)-derived TNFis are associated with development of immunogenicity resulting in low circulating drug levels ().1 A genetic predictor of immunogenicity would have clinical utility by providing a pretreatment biomarker that could be used to inform therapy selection. Previous genetic studies of TNFi immunogenicity have focused on alleles within the HLA locus on chromosome 6.2–4 Patients were followed for 12 months with serum samples collected at 3 months, 6 months and 12 months following commencement on adalimumab (TNFi) therapy. Neutralising antidrug antibodies (ADAs) were detected using a drug-sensitive/drug-tolerant radioimmunoassay (Sanquin, NL). The presence of ADAs was determined by radioimmunoassay. A positive ADA titre was defined as >12 arbitrary units/mL. If a patient developed ADA at any time in the study, they were classed as...

Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Yap, C. F., Nair, N., de Vries, A., Loeff, F. C., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A., Plant, D. Tags: Open access, ARD Letter Source Type: research